Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrimeC in Subjects With ALS
NCT05357950Phase 2Completed
- Sponsor
- NeuroSense Therapeutics
- Start
- May 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of PrimeC in amyotrophic lateral sclerosis (ALS), sponsored by NeuroSense Therapeutics. Started May 2022; status: completed.
02
Drugs
PrimeC
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05357950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357950.